The GC gene encodes vitamin D binding protein (VDBP/DBP)¹¹ vitamin D binding protein (VDBP/DBP)
A 58-kDa glycoprotein produced mainly by the liver that carries 85-90% of all circulating 25(OH)D and 85% of 1,25(OH)₂D in the bloodstream. Less than 1% of vitamin D metabolites circulate unbound (free). Only the free fraction and the smaller albumin-bound fraction are considered biologically available to enter cells, the principal carrier that transports vitamin D metabolites through the blood. rs705117 is an intronic variant in GC that has been independently associated with circulating VDBP concentrations — separate from the well-known isoform-defining variants rs4588 and rs7041. Individuals carrying certain alleles at rs705117 produce systematically lower VDBP, which creates an important paradox: lower total 25(OH)D on a standard blood test may coexist with normal or even elevated free, biologically active vitamin D²² lower total 25(OH)D on a standard blood test may coexist with normal or even elevated free, biologically active vitamin D
The "free hormone hypothesis" holds that only unbound hormone is biologically active. When VDBP is genetically low, a smaller fraction of vitamin D is sequestered, raising the free fraction. The net biological effect depends on how much VDBP is reduced and on other pathway variants.

The Mechanism

rs705117 sits in intron 10 of the GC gene on chromosome 4 (GRCh38 position 71742398). As an intronic variant, it does not alter the VDBP protein sequence directly; instead, it likely influences GC gene transcription or mRNA processing³³ GC gene transcription or mRNA processing
Intronic variants can affect splicing efficiency, polyadenylation signals, or regulatory element binding — all of which modulate how much protein the gene produces without changing its amino acid sequence, resulting in measurably different circulating VDBP concentrations between genotype groups.

In a targeted genome-wide association study of serum VDBP⁴⁴ genome-wide association study of serum VDBP
Moy KA et al. Genome-wide association study of circulating vitamin D-binding protein. Am J Clin Nutr, 2014, rs705117 emerged as one of two independent signals in the GC gene significantly associated with circulating DBP levels (P = 4.7 × 10⁻⁹¹). Mean DBP concentrations differed three-fold across genotype groups. This effect was observed independently of the classical isoform-defining variants (rs7041 Asp432Glu), demonstrating that rs705117 captures a separate component of genetically determined VDBP variation.

The T allele at rs705117 haplotypes with the rs2282679-G allele (the main GWAS signal at the GC locus for lower 25(OH)D) and is part of the GC haplotype TGA⁵⁵ GC haplotype TGA
rs705117-T + rs2282679-G + rs1491710-A; identified in a Chinese haplotype analysis as the risk combination for lower 25(OH)D concentration. Zhang et al. 2013 (PMID 23505139) associated with lower vitamin D levels.

The Evidence

The GWAS by Moy et al. 2014⁶⁶ Moy et al. 2014
Moy KA et al. Genome-wide association study of circulating vitamin D-binding protein. Am J Clin Nutr, 2014;99(6):1424-31 in 1,380 men demonstrated a striking dose-response relationship at rs705117: individuals with 0, 1, or 2 copies of the minor allele had mean VDBP concentrations of 6,339, 4,280, and 2,341 nmol/L, respectively — an approximate three-fold difference between homozygote groups.

A haplotype analysis in 2,897 healthy Chinese subjects⁷⁷ 2,897 healthy Chinese subjects
Zhang Z et al. An analysis of the association between the vitamin D pathway and serum 25-hydroxyvitamin D levels in a healthy Chinese population. J Bone Miner Res, 2013;28(8):1784-92 confirmed rs705117 as part of a GC haplotype associated with lower 25(OH)D (each additional risk allele associated with a 0.12-fold decrease in log-25(OH)D, P = 3.7 × 10⁻¹²). The overall GC locus — encompassing rs705117, rs2282679, rs4588, and rs7041 — is the strongest common genetic determinant of vitamin D status, accounting for approximately 2-7% of variance in 25(OH)D concentrations in most European populations.

The landmark SUNLIGHT consortium GWAS⁸⁸ SUNLIGHT consortium GWAS
Wang TJ et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet, 2010;376(9736):180-8 of 33,996 Europeans found that a composite genetic risk score combining GC and two other loci conferred an OR of 2.47 (95% CI 2.20-2.78) for vitamin D insufficiency. rs705117 sits within the same GC region.

The free-vitamin-D paradox has clear clinical implications: a review by Jassil et al. 2017⁹⁹ Jassil et al. 2017
Jassil NK et al. Vitamin D binding protein and 25-hydroxyvitamin D levels: emerging clinical applications. Endocr Pract, 2017;23(5):605-13 confirms that because less than 1% of vitamin D circulates unbound, any genetic reduction in VDBP necessarily shifts the free-to-total ratio — meaning standard serum 25(OH)D measurements systematically underestimate available vitamin D in low-VDBP carriers.

Practical Implications

TT carriers face a decision point when their serum 25(OH)D comes back in the borderline range (20-30 ng/mL or 50-75 nmol/L): the result may reflect genetically lower VDBP concentration rather than true vitamin D deficiency. Requesting a free 25(OH)D measurement alongside the standard total test provides a more complete picture. When supplementing, TT carriers should target the mid-range of the sufficiency window (40-60 ng/mL total) rather than pushing to the upper limit, since their free fraction may already be adequate.

Interactions

rs705117 operates within the same GC gene as rs4588 (Thr436Lys, isoform-defining) and rs7041 (Asp432Glu, isoform-defining), and is in partial linkage disequilibrium with the GWAS tag SNP rs2282679. The T allele at rs705117 co-haplotypes with the lower-VDBP alleles at these neighboring variants, compounding their effects. A carrier of both rs705117-TT and rs4588-TT (Gc2/Gc2) will have substantially lower total 25(OH)D than either variant alone predicts, with the greatest potential discordance between total and free vitamin D status.

Downstream, the practical effect of low VDBP intersects with the VDR receptor (rs2228570 / rs1544410) and the 25-hydroxylase CYP2R1 (rs10741657). If hepatic activation of vitamin D is also reduced (CYP2R1 risk allele), lower VDBP compounds the insufficiency because there is less 25(OH)D to distribute in the first place.

Inside every cell, folate is trapped in a useful form: attached to chains of glutamate molecules called polyglutamates¹¹ polyglutamates
Polyglutamate tails: chains of glutamic acid added to folate molecules that anchor them inside cells, making folate more concentrated and metabolically active than the free monoglutamate form that circulates in blood. This trapping is essential — polyglutamated folate is the working form that enzymes in the methylation cycle and nucleotide synthesis actually use. GGH (gamma-glutamyl hydrolase) is the enzyme that cuts these glutamate chains off, converting polyglutamates back to monoglutamates that can leave the cell. The -124T>G promoter variant (rs11545076) increases GGH expression, meaning more of this enzyme is produced — which speeds up the hydrolysis of intracellular folate stores and reduces how much folate the cell can retain.

The Mechanism

The GGH gene sits on chromosome 8q12.3 on the minus (reverse) strand. Its promoter controls how much GGH protein is made. The rs11545076 variant is a T-to-G change at position -124 relative to the translation start (described in papers as coding-strand notation; on the genomic plus strand, this appears as an A-to-C change). Luciferase reporter assays²² Luciferase reporter assays
DeVos et al., 2003 — Identification of SNPs in GGH, Mutat Res 2003 in HepG2 (liver) and MCF-7 (breast) cells showed that the -124G allele significantly increased promoter activity compared to the wild-type -124T allele. Higher GGH activity accelerates the cleavage of polyglutamylated folate to monoglutamylated folate, which is then exported from the cell. The net effect is reduced intracellular folate retention — less folate available for thymidylate synthesis³³ thymidylate synthesis
Thymidylate synthesis: the biochemical pathway that makes thymidine (T), one of the four DNA bases. Folate is the methyl donor in this reaction; folate shortage leads to uracil being misincorporated in place of thymine and methylation reactions.

The Evidence

The clearest human evidence comes from a study of 899 adults⁴⁴ study of 899 adults
DeVos L et al. Associations between SNPs in folate uptake and metabolizing genes with blood folate, homocysteine, and DNA uracil. Am J Clin Nutr, 2008 measuring DNA uracil content — a sensitive marker of intracellular folate sufficiency, since folate shortage causes uracil to be misincorporated into DNA instead of thymidine. Carriers of one C allele (AC genotype; TG in coding notation) had 30% higher DNA uracil levels than AA homozygotes; those with two C alleles (CC; GG in coding notation) had 73% higher DNA uracil (P for trend = 0.022). Crucially, this effect was independent of plasma folate and plasma homocysteine levels — meaning standard blood tests for folate status would appear normal even when intracellular folate is depleted at the cellular level.

In a cohort of 471 Singapore Chinese adults⁵⁵ cohort of 471 Singapore Chinese adults
Oppeneer SJ et al. Genetic variation in FPGS and GGH and plasma homocysteine. Mol Genet Metab, 2012, rs11545076 showed the strongest association with plasma homocysteine of nine GGH variants tested, and was the only variant to survive multiple-comparisons correction (adjusted p=0.001). Interestingly, carriers of the G allele (AC/CC genotypes) had slightly lower — not higher — homocysteine than TT homozygotes (GT: 9.3 nmol/L vs TT: 10.1 nmol/L). This apparent paradox may reflect compensatory redistribution of folate pools: when intracellular retention is reduced, more folate circulates in plasma, potentially supporting remethylation of homocysteine via methionine synthase.

Experimental manipulation of GGH expression in cancer cell lines confirms the downstream methylation effects⁶⁶ confirms the downstream methylation effects
Kim YI et al. γ-Glutamyl hydrolase modulation significantly influences global and gene-specific DNA methylation. Genes Nutr, 2015: GGH overexpression decreased global DNA methylation by 16-22% and reduced DNMT (DNA methyltransferase) activity, while GGH inhibition increased global DNA methylation by 7-15%. These findings establish a direct mechanistic link between GGH activity, intracellular folate retention, and epigenetic regulation.

Practical Actions

The C allele (G in coding notation) increases GGH expression and accelerates intracellular folate depletion. Because plasma folate levels may appear normal despite cellular depletion, standard serum folate tests can miss this effect. Optimizing dietary folate intake from natural sources (leafy greens, legumes, liver) — which arrives as polyglutamates that may be better retained even with elevated GGH — is preferable to relying solely on folic acid supplements. Methylfolate (5-MTHF) supplementation directly provides the active form without requiring intracellular conversion. Monitoring DNA methylation markers or homocysteine as a proxy for folate cycle function may help assess personal folate sufficiency. Individuals carrying the C allele who also have impaired folate conversion (MTHFR C677T) face a compound challenge: reduced conversion capacity plus accelerated intracellular depletion.

Interactions

The most clinically significant interaction is with MTHFR C677T (rs1801133). GGH accelerates cellular folate export while MTHFR C677T impairs conversion of dietary folate to the active methylfolate form. Together, AC or CC at rs11545076 combined with AG or AA at rs1801133 creates a compound reduction in effective intracellular folate: the cell receives less active folate due to impaired conversion, AND retains it less efficiently due to elevated GGH activity. This combination may warrant higher methylfolate doses than either variant alone.

GGH also controls intracellular levels of methotrexate polyglutamates. The related variant rs11545078 (GGH c.452C>T, coding region) reduces GGH activity and paradoxically increases MTX polyglutamate accumulation, causing methotrexate toxicity — the opposite direction from rs11545076. These two variants can co-occur and have opposing effects on methotrexate efficacy. The promoter variant rs3758149 (-401C>T, also listed as C-401T) has similar direction effects to rs11545076 and is in partial linkage disequilibrium.

IGF2BP2 is an mRNA-binding protein with an unusual job: it acts as a post-transcriptional regulator of insulin-like growth factor 2 (IGF2), a signaling molecule critical for pancreatic development, beta cell survival, and adipose tissue metabolism. The rs11705701 variant sits about 2 kilobases upstream of the gene and subtly rewires how IGF2BP2 protein is produced — not eliminating it, but shifting which version of the protein dominates in key metabolic tissues.

The Mechanism

The IGF2BP2 gene produces two major protein isoforms: p66 (the full-length form with both RNA-binding domains intact) and p58 (a shorter isoform lacking the N-terminal RRM1 domain). These isoforms are not functionally equivalent. The p58 isoform appears to act as a post-transcriptional brake¹¹ post-transcriptional brake
A regulatory mechanism that modulates how much IGF2 protein is produced from existing mRNA transcript, helping to tune IGF2 output at the tissue level.

The A allele at rs11705701 shifts this balance: research in visceral adipose tissue²² research in visceral adipose tissue
Grishina et al. IGF2BP2 mRNA and protein levels in adipose tissue. Review of Diabetic Studies, 2013 shows that AA homozygotes have reduced p58 and elevated p66 levels. Because p58 lacks the first RNA-recognition motif, reduced p58 availability may disinhibit IGF2 mRNA translation, dysregulating the IGF2 signaling axis in adipose and islet tissue.

IGF2BP2 also functions as an m6A reader³³ m6A reader
A protein that recognizes and binds to N6-methyladenosine modifications on mRNA, a major form of epitranscriptomic regulation — it directly binds PDX1 mRNA (a master transcription factor for beta cell identity) and stimulates its translation. Pancreatic beta-cell-specific knockout studies⁴⁴ Pancreatic beta-cell-specific knockout studies
PMC8076713 — IMP2 deletion reduces compensatory beta cell proliferation by 70% and impairs glucose-stimulated insulin secretion show that loss of IGF2BP2 function dramatically impairs beta cell proliferation and insulin secretion, establishing the gene's critical role in islet homeostasis.

The Evidence

The clearest functional evidence comes from a Russian case-control study (n=2,917)⁵⁵ Russian case-control study (n=2,917)
Grishina et al. Review of Diabetic Studies, 2013 in which the A allele was associated with T2D risk (OR=1.19, p<0.001). In non-diabetic AA homozygotes, the metabolic phenotype was already visible: higher HOMA-IR (p=0.04), lower HOMA-β (p=0.012), and reduced two-hour insulin levels (p=0.016) — hallmarks of combined insulin resistance and early secretory insufficiency.

A European study using hyperglycaemic clamps⁶⁶ hyperglycaemic clamps
A gold-standard technique that holds blood glucose at a fixed elevated level while measuring insulin secretion in real time found that IGF2BP2 variants were associated with a 28% reduction in first-phase insulin secretion⁷⁷ 28% reduction in first-phase insulin secretion
Staiger et al. Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion. Diabetologia, 2008 (n=272 NGT/IGT subjects, Netherlands and Germany), placing IGF2BP2 among the genes where T2D risk is mediated primarily through beta cell dysfunction rather than peripheral insulin resistance alone.

In Mexican Americans from the BetaGene family study (n=717), rs11705701 showed a significant interaction with adiposity⁸⁸ rs11705701 showed a significant interaction with adiposity
Knowles et al. Variation in IGF2BP2 interacts with adiposity to alter insulin sensitivity. Diabetes, 2015: each A allele was associated with ~1.5–2% lower body fat percentage. However, at higher adiposity, AA homozygotes showed the steepest decline in insulin sensitivity — meaning the A allele's effect on insulin signaling appears to be amplified by excess body fat.

Evidence is not uniformly positive. A Chinese prediabetes study (n=1,536) found an association only in females under a dominant model, and a 2024 gestational diabetes study (n=1,703) found no significant association⁹⁹ found no significant association
Zheng et al. PLoS One, 2024 for rs11705701 specifically. The variant may be a proxy marker for a nearby causal variant rather than functional itself, and population-specific LD patterns explain some of the heterogeneity across ethnicities.

Overall, the evidence supports a moderate classification: replicated signal in multiple populations and datasets, plausible mechanistic basis, but inconsistent across ethnicities and short of clinical-grade evidence.

Practical Implications

The combined phenotype — reduced beta cell reserve combined with impaired insulin sensitivity that worsens with adiposity — defines the actionable target: keep visceral fat low enough that the metabolic interaction stays in the favorable zone. This variant specifically identifies carriers who are likely to convert from insulin-sensitive to insulin-resistant more rapidly as body fat rises. Monitoring fasting insulin and two-hour post-load glucose provides earlier warning than HbA1c alone for this genotype.

The finding that p58 isoform reduction alters IGF2 pathway activity in both adipose and islet tissue suggests that interventions supporting insulin signaling efficiency (adequate chromium, zinc, and inositol as cofactors; low-glycaemic dietary pattern) are mechanistically relevant, not generic.

Interactions

The most clinically important interaction for this variant is with TCF7L2 rs7903146, the strongest single T2D GWAS signal. Both IGF2BP2 and TCF7L2 act in beta cell regulatory circuits — TCF7L2 through Wnt signaling and IGF2BP2 through IGF2/PDX1 axis. Carriers of risk alleles at both loci may carry compounded beta cell dysfunction, warranting especially proactive insulin secretory reserve monitoring.

rs11705701 is in partial but not complete linkage disequilibrium with rs4402960, the originally reported IGF2BP2 GWAS hit from the first wave of T2D genome-wide studies. In Mexican Americans, the two SNPs are in strong LD (D′≈1, r²≈0.95), but they tag different functional effects in some other populations, suggesting each contributes independently to metabolic risk.

The CD58 gene¹¹ CD58 gene
CD58 encodes LFA-3 (Lymphocyte Function-Associated Antigen 3), a cell-surface glycoprotein that binds CD2 on T cells to stabilise the immune synapse and promote regulatory T cell expansion harbours a cluster of intronic variants in its first intron that collectively regulate LFA-3 expression and multiple sclerosis susceptibility. The rs12044852 C/A polymorphism is one of three strongly associated markers in this locus (alongside rs2300747 and rs1335532), linked by very high linkage disequilibrium (r²=0.929 between rs12044852 and rs2300747). What distinguishes rs12044852 from its LD partner is its documented pharmacogenomic relevance: the CC genotype not only elevates MS risk but also predicts poor response to interferon-beta, the most widely prescribed first-line MS therapy.

The Mechanism

Like its LD partner rs2300747, the rs12044852 C/A polymorphism sits within the first intron of CD58 and modulates LFA-3 (CD58) mRNA expression²² LFA-3 (CD58) mRNA expression
Higher LFA-3 expression strengthens CD2-mediated costimulatory signalling in regulatory T cells (Tregs), promoting FoxP3 expression and self-tolerance. The protective A allele is associated with higher CD58 mRNA levels, mirroring the effect seen at the companion rs2300747(G) allele. Carriers of the A allele therefore have a more robust CD2–LFA-3 interaction, driving stronger Treg induction and better immune self-regulation.

For IFN-beta response, the mechanism likely connects through CD58's role in modulating T-regulatory cell potency³³ T-regulatory cell potency
IFN-beta partly exerts its anti-inflammatory effect in MS by augmenting Treg numbers and function; impaired baseline Treg activity from CD58 deficiency may blunt this therapeutic leverage. Patients who start with a CD58-deficient immune set-point (CC genotype) may derive less clinical benefit from an immunomodulatory agent that depends on intact Treg circuitry. The shared intronic haplotype block also encodes hsa-miR-548ac⁴⁴ hsa-miR-548ac
A microRNA co-transcribed from the CD58 first intron; the risk haplotype raises miR-548ac and lowers CD58 mRNA from the same primary transcript via altered Drosha cleavage, whose elevated expression in risk carriers may further suppress immunoregulatory target genes relevant to IFN-beta signalling.

The Evidence

MS susceptibility: A case-control study by Omrani et al. 2015⁵⁵ Omrani et al. 2015
200 RRMS patients vs 200 healthy controls, Iranian population; genotyping by PCR-SSP; Hardy-Weinberg confirmed in both groups found the CC genotype in 83.5% of MS patients versus 69.5% of controls, yielding an OR of 2.22 (P=0.001). The A allele (minor allele, ~10% in Europeans) acts protectively: AA individuals were significantly less likely to have MS. This mirrors the pattern at the LD-partner rs2300747, where the G (minor) allele is protective, and is consistent with the shared haplotype interpretation that the same regulatory region drives both associations.

Independent replication by Booth et al. 2008 in 1,134 Australian MS cases and 1,265 controls⁶⁶ Booth et al. 2008 in 1,134 Australian MS cases and 1,265 controls confirmed CD58 rs12044852 as a susceptibility variant (P=0.042). The broader CD58 locus was confirmed at genome-wide significance (P=4×10⁻⁹) by Hoppenbrouwers et al. 2009⁷⁷ Hoppenbrouwers et al. 2009 and is among the 57 confirmed MS susceptibility loci in the large Sawcer et al. 2011 Nature GWAS⁸⁸ Sawcer et al. 2011 Nature GWAS
9,772 cases collected by 23 research groups across 15 countries.

IFN-beta response: Among 120 relapsing-remitting MS patients receiving IFN-beta therapy and followed over two years, Omrani et al.⁹⁹ Omrani et al. found striking genotype-stratified differences in Multiple Sclerosis Severity Score trajectory. The ΔMSSS (change from baseline) was 0.44 for CC carriers — the worst outcome group — compared with 0.03 for AC carriers (best responders) and 0.11 for AA carriers. The association between CC genotype and poor IFN-beta response was statistically significant (P<0.05). This is the first pharmacogenomic annotation of rs12044852 and represents the primary clinical utility distinguishing it from rs2300747.

Population genetics: the C allele is very common in Europeans (~90%) and Africans (~93%), but notably less so in East Asians (~42%), paralleling the lower MS burden in East Asian populations and matching the inverse pattern seen at rs2300747's protective G allele.

Practical Actions

For CC carriers — the large majority of European-descent individuals — the two key clinical implications are: (1) modest but real elevation of MS susceptibility requiring awareness of early warning signs and attention to modifiable risk factors, especially vitamin D; and (2) if MS develops and IFN-beta therapy is being considered, this genotype signals a higher likelihood of suboptimal therapeutic response. Discussing this with a neurologist before committing to IFN-beta over alternative disease-modifying therapies (natalizumab, ocrelizumab, dimethyl fumarate, or sphingosine-1-phosphate modulators) is worthwhile.

For AC or AA carriers, the protective A allele suggests better IFN-beta response and lower baseline MS susceptibility, though the A allele is rare (~10% in Europeans) and the AA genotype is uncommon (~1%).

Vitamin D optimisation is the strongest modifiable lever for all genotypes: sufficiency independently supports FoxP3 expression and Treg function through the vitamin D receptor pathway, partially compensating for reduced LFA-3-mediated Treg support.

Interactions

Within the CD58 locus, rs12044852 and rs2300747 are in near-complete LD (r²=0.929) and almost certainly tag the same functional haplotype. An individual's risk at one predicts their risk at the other. The companion variant rs1335532 is also in strong LD and appears to anchor the miR-548ac regulatory mechanism described by Hecker et al. 2019¹⁰¹⁰ Hecker et al. 2019.

The CD58 costimulatory axis intersects with rs6897932 (IL7R), which regulates T-cell homeostasis and Treg survival, and with PTPN22 rs2476601, which lowers the TCR activation threshold. Individuals carrying high-risk alleles across these loci face compounding impairments to immune self-tolerance. The pharmacogenomic IFN-beta response signal at rs12044852 adds a third dimension: genetic background may influence not just who develops MS but how well they respond to its first-line treatment.

CHI3L1 encodes YKL-40¹¹ CHI3L1 encodes YKL-40
YKL-40 is a chitinase-like protein secreted by macrophages, neutrophils, bronchial epithelial cells, and smooth muscle cells; it drives airway inflammation, bronchial wall remodeling, and smooth muscle proliferation independent of classical eosinophilic Th2 pathways, making it one of the most clinically relevant biomarkers of non-T2, severe asthma. Most genetic studies of CHI3L1 have focused on the promoter variant rs4950928 (-131C>G), which modulates transcription start site activity and produces the largest common-variant effect on circulating YKL-40 levels. rs12141494 sits in intron 6 of CHI3L1 at chr1:203,182,297 (GRCh38), a region that modulates YKL-40 expression through a distinct mechanism — and crucially, does so independently of the promoter variant.

The Mechanism

Intronic variants can regulate gene expression through splicing enhancer/silencer sequences, effects on transcription elongation, or by altering the binding of regulatory RNA or chromatin-modifying complexes to the pre-mRNA. rs12141494 is a G>A transition on the plus strand; because CHI3L1 is encoded on the minus strand, this corresponds to a C>T change on the coding strand. In specific transcript isoforms (XP_047298829.1 and XP_047298835.1), this position falls at a coding boundary and produces a proline-to-serine missense change (Pro205Ser and Pro199Ser respectively), suggesting that the intron 6 position may have functional consequences beyond pure splicing regulation. However, in the canonical CHI3L1 transcript the variant is classified as an intron variant by dbSNP. Conditional analysis in the Gomez et al. 2015 study²² Conditional analysis in the Gomez et al. 2015 study
Jose L Gomez et al., Yale and SARP cohorts, n=1,178 asthmatic subjects of European ancestry; both cohorts analyzed independently and results intersected confirmed that rs12141494 influences YKL-40 levels and FEV1 independently of rs4950928, establishing it as a second, distinct CHI3L1 regulatory locus.

The Evidence

The primary evidence for rs12141494 comes from a two-cohort study of asthma severity and airway YKL-40 expression³³ two-cohort study of asthma severity and airway YKL-40 expression
Gomez et al. J Allergy Clin Immunol 2015; 259 Yale Center for Asthma and Airways Disease subjects and 919 SARP (Severe Asthma Research Program) subjects; all of European ancestry. Of 15 CHI3L1 SNPs associated with FEV1, serum YKL-40, or both, rs12141494 (intron 6) was the only SNP in European-ancestry subjects that was consistently associated in both cohorts with serum YKL-40 levels and post-bronchodilator FEV1. The A allele at rs12141494 was associated with higher airway YKL-40 expression and worse asthma severity (P≤0.05). The G allele was associated with lower YKL-40 expression and higher FEV1 percent predicted, i.e. better preserved lung function.

The clinical importance of YKL-40 as a severity biomarker is well-established. A meta-analysis of 17 studies covering 5,696 subjects⁴⁴ meta-analysis of 17 studies covering 5,696 subjects
Jin et al. Sleep Breath 2022 confirmed that serum YKL-40 is significantly elevated in asthma versus controls, rising further with severity and acute exacerbations. YKL-40 correlates specifically with bronchial wall thickening (r=0.45), blood neutrophils (r=0.63), and exhaled nitric oxide (r=0.48) in therapy-resistant pediatric asthma⁵⁵ bronchial wall thickening (r=0.45), blood neutrophils (r=0.63), and exhaled nitric oxide (r=0.48) in therapy-resistant pediatric asthma
Konradsen et al. J Allergy Clin Immunol 2013; therapy-resistant vs controlled asthma; serum YKL-40 19.2 vs 13.8 ng/mL, P=0.03 — all markers of active airway remodeling rather than simple allergen sensitization. In a 2023 phenotype review⁶⁶ 2023 phenotype review
Specjalski et al. Front Med 2023, YKL-40 was highest in severe neutrophilic and obesity-associated asthma, correlating with therapy resistance, exacerbation frequency, and FEV1 decline.

Practical Actions

Carriers of the A allele at rs12141494 have a genetically elevated YKL-40 set-point that drives airway remodeling independently of promoter-driven YKL-40 regulation. For asthmatic A-allele carriers, serum YKL-40 measurement provides direct insight into the biological activity of this genetic predisposition. Because YKL-40 elevation is relatively steroid-insensitive (it marks non-T2 remodeling rather than eosinophilic inflammation), standard inhaled corticosteroid escalation may undertreat the remodeling process it drives. Exposure to occupational dust, mold, and biomass smoke are the principal environmental triggers documented to amplify YKL-40-driven airway remodeling, and are specifically relevant for A-allele carriers with occupational asthma or indoor air quality concerns.

Interactions

rs12141494 operates independently of the CHI3L1 promoter variant rs4950928, which is already in the GeneOps database. Carriers of the A allele at rs12141494 who also carry the C allele at rs4950928 are doubly predisposed to elevated YKL-40 through two mechanistically distinct routes: reduced transcriptional suppression (rs4950928) and altered intron 6 splicing or transcript regulation (rs12141494). The SARP/Yale study specifically confirmed the independence of these effects through conditional analysis; having risk alleles at both loci would be expected to produce the highest YKL-40 burden of any CHI3L1 genotype combination.

The SLC11A2 gene encodes Divalent Metal Transporter 1 (DMT1)¹¹ Divalent Metal Transporter 1 (DMT1)
also known as NRAMP2; the primary transporter for ferrous iron across intestinal epithelial cells and from endosomes into the cytosol, the most important protein controlling how much dietary iron enters your body. Located at chromosome 12q13.12, SLC11A2 is expressed in the duodenum, liver, kidney, and — critically for diabetes risk — in pancreatic beta cells, where iron availability directly governs insulin production and secretion. The intronic variant rs12304921 (G allele, ~17% in Europeans) lies within a regulatory region of the gene and has been genotyped in multiple type 2 diabetes (T2DM) genome-wide association studies, pointing to the SLC11A2 locus as a contributor to diabetes susceptibility through the iron-homeostasis pathway.

The Mechanism

DMT1 operates as the gatekeeper for non-heme dietary iron absorption in the duodenum: it transports ferrous iron (Fe²⁺) across the apical brush border membrane of enterocytes. Inside the cell, ferroportin then exports iron into the bloodstream. The balance between DMT1 expression (import) and ferroportin (export) determines systemic iron load. Critically, the SLC11A2 gene produces two major isoforms via alternative 3′ splicing: one containing an iron-responsive element (IRE)²² iron-responsive element (IRE)
a stem-loop structure in the 3′ UTR that stabilizes the mRNA when cellular iron is low, allowing compensatory upregulation of iron absorption in its 3′ UTR, and one lacking this element. Intronic variants near splice regulatory sequences — as rs12304921 may be — can shift the ratio between these two isoforms, altering the body's ability to sense and respond to iron status. When the IRE-containing isoform is suppressed, the body loses its adaptive capacity to upregulate iron absorption during deficiency — or, conversely, to downregulate it during overload.

Beta cells are particularly vulnerable to iron dysregulation. Pancreatic beta cells express high levels of DMT1 and accumulate iron more readily than neighboring alpha cells due to low ferroportin expression. Iron deprivation in isolated islets reduces glucose-stimulated insulin secretion by 45%³³ Iron deprivation in isolated islets reduces glucose-stimulated insulin secretion by 45%
Martínez-García et al. Cell Metab 2020; n=purified human islet subsets, while iron excess causes oxidative damage via Fenton chemistry, impairing glucose sensing and triggering beta-cell apoptosis. Transcriptome analyses comparing T2DM and control tissue have found that SLC11A2 is significantly downregulated in T2DM samples, and its expression level correlates positively with 113 of 154 insulin-secretion genes — suggesting that disrupted DMT1 function contributes to the beta-cell failure characteristic of T2DM.

The Evidence

rs12304921 was included in the genotyping arrays of several landmark T2DM GWAS studies, including the Wellcome Trust Case Control Consortium (WTCCC) 7-disease GWAS⁴⁴ Wellcome Trust Case Control Consortium (WTCCC) 7-disease GWAS
n=14,000 cases, 3,000 controls across seven diseases including T2DM and a cumulative risk SNP study in Han Chinese⁵⁵ cumulative risk SNP study in Han Chinese
Qian et al. PLoS One 2015; n=996 T2DM cases, 998 controls. These studies establish that the SLC11A2 locus is relevant to T2DM genetic architecture across diverse populations, particularly given the notably higher G allele frequency in East Asian populations (~50%) compared to Europeans (~17%).

A Turkish case-control study examined SLC11A2 intronic polymorphisms directly in 100 T2DM patients versus 100 healthy controls and found that the homozygous risk genotype was significantly associated with T2DM risk under a recessive model (P=0.030 for homozygotes; P=0.037 recessive model)⁶⁶ (P=0.030 for homozygotes; P=0.037 recessive model)
Ozbayer et al. J Genet 2018, PMID 30555088, with the risk genotype carriers showing higher blood iron levels — consistent with disrupted iron regulation as the underlying mechanism.

At the gene-expression level, a transcriptome meta-analysis found that SLC11A2 and TFRC (transferrin receptor) are significantly downregulated in T2DM tissue⁷⁷ SLC11A2 and TFRC (transferrin receptor) are significantly downregulated in T2DM tissue
Yang et al. Diabetol Metab Syndr 2023, with SLC11A2 expression positively correlating with 73% of insulin-secretion genes. A meta-analysis of iron biomarkers and T2DM found that elevated serum ferritin (a marker of iron stores) is associated with a 70% increased T2DM risk, and interventional phlebotomy studies show that reducing iron stores improves insulin sensitivity and beta-cell function in pre-diabetic individuals.

At this time, rs12304921 has not reached genome-wide significance as a standalone T2DM locus, and the evidence is classified as emerging. The biological mechanism connecting SLC11A2 to T2DM is well-established; the specific contribution of this intronic variant requires further functional characterization.

Practical Implications

G allele carriers have potential for altered iron absorption regulation, which may manifest as higher baseline iron stores or impaired adaptive upregulation during iron deficiency. Given the U-shaped relationship between iron status and T2DM risk — both very low and very high iron are harmful — monitoring serum ferritin is the key actionable insight. GG homozygotes carry the greatest potential for altered iron homeostasis. Avoiding supplemental iron unless deficiency is confirmed by blood tests is particularly important, since excess iron loads the pancreatic beta cells with ferrous iron that generates oxidative damage.

Interactions

SLC11A2 function interacts with several other iron-homeostasis genes: HFE (rs1799945, C282Y) mutations cause hereditary hemochromatosis through hepcidin dysregulation upstream of DMT1; TMPRSS6 (rs855791) regulates hepcidin synthesis, the master iron hormone that suppresses DMT1 at the duodenum. Carriers of both rs12304921 G and HFE C282Y may accumulate iron more rapidly than either variant alone predicts, as DMT1 dysregulation combined with reduced hepcidin signaling removes two separate brakes on iron absorption. These potential gene-gene interactions warrant a combined monitoring approach in carriers.

Apolipoprotein B-100 (ApoB) is the structural backbone of LDL particles — every LDL particle carries exactly one ApoB-100 protein, and it is this protein that docks with the LDL receptor on liver cells to clear LDL from the bloodstream. The rs12713559 variant causes a cysteine to replace an arginine at position 3558 of the ApoB protein, in the segment responsible for LDL receptor binding. This disrupts LDL clearance, but to a degree that varies considerably between individuals.

The Mechanism

The p.Arg3558Cys substitution (historically called R3531C in earlier numbering systems) sits within the proposed LDL receptor-binding domain of ApoB. Arginine at position 3558 contributes to the cluster of positively charged residues that interact electrostatically with the LDL receptor. Replacing it with cysteine introduces a sulfhydryl group and removes a positive charge, impairing the ApoB-LDL receptor interaction.

Functional assays¹¹ Functional assays
Pullinger CR et al. Familial ligand-defective apolipoprotein B. Identification of a new mutation that decreases LDL receptor binding affinity. J Clin Invest, 1995 show that LDL particles from R3558C heterozygotes bind to the LDL receptor at roughly 50-63% of normal affinity. In competitive binding assays using U937 cells, the defective particles were 74% as effective as normal LDL and accumulated preferentially compared to the wild-type allotype — meaning mutant LDL persists longer in circulation.

The Evidence

The discovery report²² discovery report
Pullinger CR et al. J Clin Invest, 1995 identified the variant in two unrelated families; all eight carriers showed elevated cholesterol (mean 240 mg/dL) versus unaffected relatives (185 mg/dL). The gene sits on the minus strand; the coding-strand change is C>T at position 10672 of NM_000384.3.

A larger kindred study³³ larger kindred study
Ouguerram K et al. The apolipoprotein B R3531C mutation. Characteristics of 24 subjects from 9 kindreds. J Lipid Res, 1999 of 24 carriers from 9 kindreds confirmed the binding deficit but found highly variable LDL cholesterol expression, modulated by environmental and other genetic factors.

Crucially, a large population-based study⁴⁴ population-based study
Tybjaerg-Hansen A et al. Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease. NEJM, 1998 of 9,255 Danish individuals found R3558C heterozygotes (0.08% prevalence) did not have higher-than-normal plasma cholesterol levels, and the association with ischemic heart disease was not significant (OR 1.4, 95% CI 0.2-11, p=0.54). This contrasts sharply with the well-characterized R3500Q variant (rs5742904), which is 10-fold more prevalent and is a well-established cause of familial defective apolipoprotein B (FDB) with OR 7.0 for ischemic heart disease.

A family-based segregation study⁵⁵ family-based segregation study
Rabes JP et al. R3531C mutation in the apolipoprotein B gene is not sufficient to cause hypercholesterolemia. Atherosclerosis, 2000 found that 6 of 10 R3558C carriers had normal cholesterol, with the mean cholesterol not significantly different between carriers and non-carriers. A co-segregating LDLR mutation was the primary driver of hypercholesterolemia in that family, with R3558C potentially acting as a modifier.

ClinVar now records 14 of 18 submissions as uncertain significance (last updated February 2026). The 1995 OMIM pathogenic entry and one Italian laboratory's "likely pathogenic" call are flagged as not meeting current evidence criteria.

Practical Actions

Because the clinical significance of this variant remains genuinely uncertain, the most appropriate response is cardiovascular risk monitoring through regular lipid panels, not preemptive treatment. Many carriers have normal cholesterol. If LDL is elevated, standard FH-adjacent management applies: dietary saturated fat restriction and statin therapy if needed. The variant does not affect statin mechanism — statins upregulate the LDL receptor, so even with reduced ApoB-LDL receptor affinity, statin response should be intact.

If you are heterozygous for this variant and have elevated LDL cholesterol, genetic testing for LDLR mutations is warranted, as co-occurring LDLR mutations may be driving the lipid phenotype.

Interactions

The clinically important interaction is between rs12713559 and LDLR mutations (not catalogued in this database). Rabes et al. (2000) found that R3558C alone did not cause hypercholesterolemia but may amplify the effect of a concurrent LDLR defect. The related and far more common APOB R3500Q variant (rs5742904) is the canonical cause of familial defective apolipoprotein B; if you also carry APOE E4 (rs429358), independent cardiovascular risk factors stack.

When Tanaka and colleagues performed a genome-wide association study in Japanese hepatitis C patients in 2009, two variants near the IL28B gene emerged with striking statistical force: rs8099917 and rs12980275. The latter — a simple A-to-G change on chromosome 19 — reached P=1.93×10⁻¹³ for null virological response and P=3.99×10⁻²⁴ for sustained virologic response, making it one of the most significant host genetic associations in hepatitis C pharmacogenomics. While rs12979860 later became the standard marker in European clinical practice, rs12980275 remains the preferred tag in Asian populations and HCV genotype-4 testing panels.

The variant sits approximately 1 kilobase downstream of the IFNL3 (formerly IL28B) gene on chromosome 19q13.13, in a regulatory region that influences expression of interferon lambda-3¹¹ interferon lambda-3
one of four type III interferons that restrict viral replication at mucosal and hepatic surfaces by activating the JAK-STAT pathway in epithelial cells and hepatocytes. The G allele at rs12980275 is in strong linkage disequilibrium²² linkage disequilibrium
non-random co-inheritance of nearby genetic variants with the T allele of rs12979860 (r²=0.68–1.0 depending on population) — meaning both tag the same underlying IFNL3/IFNL4 haplotype that impairs antiviral immunity.

The Mechanism

rs12980275 does not alter any protein sequence; its effect is regulatory. The G allele tags the same unfavourable haplotype across the IFNL3/IFNL4 region as rs12979860 T and rs8099917 G. On this haplotype, the functional causal variant is the ss469415590 frameshift (rs368234815)³³ ss469415590 frameshift (rs368234815)
a dinucleotide variant in IFNL4 intron 1 that either creates or destroys functional interferon lambda-4 protein. The ΔG allele at rs368234815 — tagged by rs12980275 G — produces functional IFN-λ4 protein, which paradoxically impairs hepatitis C clearance by inducing endoplasmic reticulum stress in hepatocytes, pre-activating interferon-stimulated genes in ways that desensitise cells to exogenous interferon treatment, and dampening HCV-specific CD8+ T-cell responses.

The rs12980275 G allele also tags regulatory elements controlling IFNL3 transcription itself. In a haemodialysis cohort, the AG genotype was associated with elevated plasma IFN-λ3 levels, suggesting the variant influences IFNL3 expression in a complex dosage-dependent manner that differs between heterozygotes and GG homozygotes.

The Evidence

The Tanaka et al. 2009 GWAS⁴⁴ Tanaka et al. 2009 GWAS in Japanese HCV genotype-1 patients was the discovery study for this marker. SVR rates declined sharply across genotypes: AA patients achieved approximately 76.9% SVR, while GG patients achieved only 12.5% — a striking gradient that established the clinical importance of this locus in Asian populations.

A meta-analysis of 16 studies comprising 2,786 patients⁵⁵ meta-analysis of 16 studies comprising 2,786 patients found the AA genotype predicts significantly higher SVR than AG/GG genotypes with peginterferon/ribavirin. The overall odds ratio was approximately 2.88; in the Asian subgroup it was OR 3.08 (95% CI 1.45–6.54) and in Caucasians it was OR 2.74 (95% CI 1.53–4.92). The association held specifically for HCV genotypes 1 and 4.

In a Chinese Han cohort of 238 patients, rs12980275 AA was the only IL28B marker independently associated with rapid viral response⁶⁶ rs12980275 AA was the only IL28B marker independently associated with rapid viral response. Carriers of AG/GG genotypes had an adjusted OR of 0.43 (95% CI 0.24–0.75) for achieving rapid viral response, confirming the G allele's predictive value specifically in this population.

Notably, in Korean patients where the AA genotype frequency reaches 87.2% and the GG genotype is essentially absent, IL28B testing including rs12980275 was found to have limited clinical utility precisely because the favourable genotype predominates. This mirrors the broader pattern across East Asia: the G allele frequency is only ~10% in East Asians compared to ~31% in Europeans and ~51% in Africans, making rs12980275 most clinically relevant in mixed or non-East-Asian populations.

Beyond hepatitis C, the G allele has been linked to impaired antiviral responses more broadly. In a Spanish surgical cohort, GG homozygotes had a 2.15-fold higher adjusted hazard of 28-day mortality during septic shock⁷⁷ GG homozygotes had a 2.15-fold higher adjusted hazard of 28-day mortality during septic shock compared to AA carriers, consistent with impaired innate immune defence. In COVID-19 patients, the AA genotype was significantly enriched in survivors versus non-survivors⁸⁸ the AA genotype was significantly enriched in survivors versus non-survivors, with GG genotype independently associated with severe disease in multivariate analysis.

Practical Actions

For hepatitis C management, rs12980275 provides essentially the same clinical information as rs12979860 in most populations. With modern pangenotypic direct-acting antivirals (DAAs), overall SVR rates exceed 95% regardless of IFNL3 genotype. The variant's main clinical relevance today lies in treatment duration decisions: GG carriers are not candidates for abbreviated 8-week protocols and should receive full 12-week courses. The variant also retains value for predicting the likelihood of spontaneous clearance in acute HCV infection.

For non-HCV health contexts, the G allele signal across septic shock and COVID-19 mortality suggests GG carriers have a broadly attenuated innate antiviral and antibacterial response, making vaccination and early treatment adherence particularly important.

Interactions

rs12980275 is in strong linkage disequilibrium with rs12979860⁹⁹ linkage disequilibrium with rs12979860
r²=0.68–1.0 depending on population; both tag the same IFNL4/3 haplotype but with varying predictive weights across ancestries, and with rs8099917¹⁰¹⁰ rs8099917
also in LD across the IFNL3/4 locus; the two were co-identified in the original Japanese GWAS, and with rs368234815¹¹¹¹ rs368234815
the true causal frameshift in IFNL4 that determines whether functional IFN-λ4 protein is produced. Commercial HCV pharmacogenomics panels often include rs12980275 alongside rs12979860 and rs8099917 because no single marker provides complete predictive information across all ancestries. The variants should not be treated as independent effects — they all tag the same underlying functional haplotype.

The PER3 gene¹¹ PER3 gene
Period Circadian Regulator 3, one of three Period proteins that form the negative feedback arm of the molecular circadian clock is a master timekeeper in every cell of your body. Its protein accumulates during the day, enters the nucleus, and shuts down the very transcription machinery that made it — completing one oscillation roughly every 24 hours. The rs150812083 variant swaps a proline for an alanine at position 415, and the consequences reach all the way from molecular clock mechanics to sleep timing, seasonal mood, and family history of early-rising disorder.

This variant is rare — found in roughly 1 in 200 people of European descent — but its effect is dramatic. It was first identified as the cause of familial advanced sleep phase syndrome 3 (FASPS3)²² familial advanced sleep phase syndrome 3 (FASPS3)
An autosomal dominant circadian rhythm disorder in which affected individuals fall asleep and wake approximately 4 hours earlier than average, with sleep onset around 6-8 PM and spontaneous waking around 4 AM, and later confirmed as a strong morningness signal in the largest chronotype GWAS to date.

The Mechanism

At position 415, proline is a structurally rigid amino acid that imposes a sharp bend in the local protein chain. The G allele substitutes the flexible alanine, disrupting a conserved region near the CRY-binding interface³³ CRY-binding interface
CRY1/CRY2 proteins partner with PER proteins to form the transcriptional repressor complex that feeds back to inhibit CLOCK-BMAL1 activity.

The functional consequence, shown in Zhang et al. 2016⁴⁴ Zhang et al. 2016
Zhang L et al. A PERIOD3 variant causes a circadian phenotype and is associated with a seasonal mood trait. PNAS, 2016., is counterintuitive: the Pro415Ala protein is less stable than wild-type — it degrades faster, accumulates to lower nuclear levels despite higher mRNA production, and loses repressor efficiency. Without sufficient PER3 to dampen the CLOCK-BMAL1 feedback loop, the clock cycles more rapidly — shortening the intrinsic circadian period and advancing the entire sleep-wake cycle.

The same variant also impairs PER3's ability to stabilize PER1 and PER2 proteins, compounding the clock acceleration. Transgenic mice expressing the human P415A/H417R allele showed an altered circadian period under constant light conditions and, strikingly, showed phase-shifted activity and depression-like behavior in short photoperiod conditions mimicking winter — directly linking this circadian variant to seasonal affective disorder (SAD).

The Evidence

The variant was first described in a three-generation family with FASPS3 by Zhang et al. (PNAS, 2016)⁵⁵ Zhang et al. (PNAS, 2016)
Zhang L et al. A PERIOD3 variant causes a circadian phenotype and is associated with a seasonal mood trait. PNAS 113(11):E1536-44.. Affected members fell asleep by midnight and woke spontaneously by 8:15 AM (advanced by ~4 hours relative to population average), and scored at the 99th percentile for seasonal mood variation — with worst symptoms in December and January. The variant co-occurs on the same chromosome copy as a second change (rs139315125, H417R); in vitro studies showed both positions contribute to protein destabilization.

At the population scale, Jones et al. (Nature Communications, 2019)⁶⁶ Jones et al. (Nature Communications, 2019)
Jones SE et al. Genome-wide association analyses of chronotype in 697,828 individuals provides insights into circadian rhythms. Nat Commun 10:343. found the G allele associated with self-reported morningness at extraordinary significance (OR=1.44, P=2×10⁻³⁸) in a meta-analysis of UK Biobank and 23andMe participants — making it one of the strongest single-variant effects on chronotype ever identified. Notably, the objective effect on sleep timing was modest (~8 minutes earlier by actigraphy), suggesting the variant's primary impact on subjective sleep experience is disproportionate to its absolute phase advance.

Practical Implications

Carriers of the G allele experience a genuine biological drive toward earlier sleep timing. Unlike lifestyle-driven early rising, this variant reflects an intrinsically faster molecular clock. The clinical consequence depends on whether your environment accommodates your advanced phase:

Early timing aligns well with standard work and school schedules, but creates problems in social contexts demanding late-night participation. The more serious concern is the seasonal mood dimension. Because PER3 governs how the circadian clock adapts to photoperiod (day length), a destabilized PER3 may impair seasonal adaptation — the same mechanism that causes winter-pattern SAD. G allele carriers in the FASPS3 family showed seasonality scores above the 97th percentile, with winter depression.

Evening bright light therapy is the most evidence-supported intervention for FASPS: light between 7 and 9 PM shifts the phase-delaying window of the circadian phase response curve⁷⁷ circadian phase response curve
The PRC describes how light exposure at different clock times shifts the circadian phase; light in the evening hours (the delay zone) pushes the clock later, counteracting the pathological advance. Morning bright light avoidance (or blue-light filtering) prevents further clock advancement on waking.

Interactions

This variant is reported on the same haplotype as rs139315125 (H417R in PER3), seven base pairs downstream. The two changes consistently co-occur in published FASPS3 families and functional studies always test them together. Either variant alone may have attenuated effects; the compound haplotype is the clinically relevant combination.

PER3 Pro415Ala sits in the same feedback loop as rs228697 (PER3 Pro864Ala) and rs35333999 (PER2 V903I). Those variants lengthen circadian period (evening-shifting), while rs150812083 shortens it (morning-shifting). An individual carrying both an evening-shifting PER2 variant and this advanced-phase PER3 variant would experience opposing forces, potentially producing an unstable or irregular circadian rhythm rather than a clean chronotype in either direction.

The seasonal mood dimension suggests potential interaction with melatonin pathway variants such as rs10830963 (MTNR1B) and serotonin transporter variants; no published studies have formally characterized these gene-gene interactions.

Your body cannot synthesize omega-3 and omega-6 fats from scratch. It starts with short-chain precursors — alpha-linolenic acid (ALA) from flaxseed and walnuts for omega-3, linoleic acid (LA) from vegetable oils for omega-6 — and extends them through a series of enzymatic steps into the longer-chain forms that actually drive biology: EPA, DHA, and arachidonic acid (AA). The rate-limiting enzyme in this pipeline is FADS1¹¹ FADS1
Fatty acid desaturase 1, also called delta-5 desaturase (D5D); catalyzes the final desaturation step converting DGLA → AA in the omega-6 pathway and ETA → EPA in the omega-3 pathway. rs174553 is an intronic variant in the FADS1 gene cluster that alters how efficiently this enzyme operates — and the difference shows up directly in your blood.

The Mechanism

As an intronic variant²² intronic variant
a DNA change within a non-coding intron; can affect gene expression through regulatory elements, splicing signals, or mRNA stability without altering the protein sequence directly, rs174553 does not change the FADS1 protein. Instead, the G allele sits in a regulatory region of the FADS1 locus that is part of a tight haplotype block across the FADS1-FADS2 cluster on chromosome 11. Multiple studies confirm that carrying the G allele — or the broader minor-allele haplotype it tags — is associated with lower FADS1 desaturase activity across both the omega-6 and omega-3 pathways.

Practically, this means: - DGLA → arachidonic acid (AA): reduced efficiency, lower circulating AA - ETA → EPA: reduced efficiency, lower endogenous EPA from dietary ALA precursors - Precursor accumulation: higher dihomo-gamma-linolenic acid (DGLA) and linoleic acid (LA), which build up when the desaturation step is slow

The A allele, which corresponds to the GRCh38 plus-strand reference at this position, is associated with normal or higher FADS1 activity.

The Evidence

The most rigorous evidence comes from a study of 224 individuals in a geographically isolated founder population³³ study of 224 individuals in a geographically isolated founder population
Mathias et al. FADS genetic variants and omega-6 polyunsaturated fatty acid metabolism in a homogeneous island population. J Lipid Res, 2010. Across 16 FADS cluster SNPs tested against 22 fatty acids, rs174553 G allele carriers showed consistently lower omega-6 long-chain PUFAs. The FADS1 omega-6 activity ratio (AA/DGLA) showed the strongest association of any fatty acid measure (p = 2.11×10⁻¹³ to 1.8×10⁻²⁰) — an exceptionally strong signal for a common intronic variant.

In pregnant and lactating women, Xie and Innis demonstrated⁴⁴ Xie and Innis demonstrated
Xie L, Innis SM. Genetic variants of the FADS1 FADS2 gene cluster are associated with altered (n-6) and (n-3) essential fatty acids in plasma and erythrocyte phospholipids in women during pregnancy and in breast milk during lactation. J Nutr, 2008 that GG homozygotes had lower arachidonic acid, lower EPA, and higher linoleic acid in both plasma phospholipids and red blood cell membranes — confirming the conversion impairment extends into tissue-level fatty acid composition, not just circulating levels.

A key clinical implication emerged from an infant RCT with 276 participants⁵⁵ infant RCT with 276 participants
Meldrum et al. Can polymorphisms in the FADS gene cluster alter the effects of fish oil supplementation on plasma and erythrocyte fatty acid profiles? Eur J Nutr, 2018 where minor G allele homozygotes across FADS1 SNPs, including rs174553, showed significantly higher DHA levels after fish oil supplementation than other genotypes. This counterintuitive finding — poor converters respond better to preformed DHA — reflects that when endogenous conversion is impaired, exogenous EPA and DHA are incorporated more efficiently because there is less competition from endogenously synthesized product.

Population frequencies vary substantially: the G allele is rare in African populations (~8%) but common in East Asian (~55%) and Latino (~49%) populations, suggesting population-specific dietary adaptations to traditional marine food sources in some ancestry groups.

Practical Actions

For G allele carriers, the core implication is that relying on plant-based omega-3 sources (ALA from flaxseed, chia, walnuts) is insufficient to maintain adequate EPA and DHA levels, because the conversion machinery is slower. GG homozygotes in particular should obtain preformed EPA and DHA directly from marine or algae-based sources, bypassing the impaired desaturation step. Target 2–4 g combined EPA+DHA daily for GG carriers; 1–2 g for AG heterozygotes. Algae-based DHA/EPA supplements are equally effective and suitable for vegetarians.

On the omega-6 side, lower FADS1 activity means less AA is produced — which reduces the substrate for pro-inflammatory eicosanoids. GG carriers may therefore have a lower baseline inflammatory tone from the omega-6 pathway, but this comes at the cost of the reduced EPA and DHA synthesis described above.

Interactions

rs174553 is in high linkage disequilibrium with rs174537, rs174547, and rs174546 in the same FADS1 haplotype block. These variants co-segregate, and carrying the minor haplotype across multiple positions compounds the reduction in desaturase activity. The nearby FADS2 gene (encoding delta-6 desaturase, which acts upstream of FADS1) also contains functionally relevant variants — combined FADS1+FADS2 impairment more severely restricts the full ALA → EPA → DHA conversion pathway than either gene alone.

The ELOVL2 gene (rs953413, rs2397142) encodes the elongase enzyme that operates between FADS steps; ELOVL2 variants that reduce elongase efficiency interact with FADS1 impairment to further reduce DHA synthesis capacity.